Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | GGPS1 | O95749 | 6/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.41 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.41 |
| ▸ | FDPS | P14324 | 8/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7106303 | 1.00 | MEN1 (0.47) | MEN1MAPTKMT2AATML3MBTL1 | |
| SCHEMBL23859895 | 1.00 | MEN1 (0.47) | MEN1MAPTKMT2AATML3MBTL1 | |
| SCHEMBL7543083 | 1.00 | MEN1 (0.47) | MEN1MAPTKMT2AATML3MBTL1 | |
| SCHEMBL25173893 | 1.00 | MEN1 (0.47) | MEN1MAPTKMT2AATML3MBTL1 | |
| SCHEMBL21679706 | 0.98 | MEN1 (0.46) | MEN1MAPTKMT2AATML3MBTL1 | |
| SCHEMBL21679707 | 0.98 | MEN1 (0.46) | MEN1MAPTKMT2AATML3MBTL1 | |
| SCHEMBL21679731 | 0.98 | MEN1 (0.46) | MEN1MAPTKMT2AATML3MBTL1 | |
| SCHEMBL21679729 | 0.98 | MEN1 (0.46) | MEN1MAPTKMT2AATML3MBTL1 | |
| SCHEMBL25200704 | 0.98 | MEN1 (0.44) | MEN1MAPTKMT2AATML3MBTL1 | |
| SCHEMBL28697224 | 0.94 | MEN1 (0.46) | MEN1MAPTKMT2AATML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137629-A1 | Novel Lipids For Delivery Of Nucleic Acid Segments | ASTRAZENECA AB (SE) | 2026-05-21 | — | — | US | disclosed |
| EP-4423095-A1 | NOVEL LIPIDS FOR DELIVERY OF NUCLEIC ACID SEGMENTS | AstraZeneca AB (SE) | 2024-09-04 | — | — | EP | disclosed |
| CN-118119627-A | Novel lipids for delivery of nucleic acid segments | 阿斯利康(瑞典)有限公司 | 2024-05-31 | — | — | CN | disclosed |
| US-20230348362-A1 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20230233468-A1 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2023-07-27 | — | — | US | disclosed |
| WO-2023125889-A1 | QUADRIVALENT MRNA VACCINES FOR INFLUENZA VIRUSES | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2023-07-06 | — | — | WO | disclosed |
| WO-2023098842-A1 | NUCLEIC ACID VACCINES FOR CORONAVIRUS BASED ON SEQUENCES DERIVED FROM SARS-CoV-2 OMICRON STRAIN | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2023-06-08 | — | — | WO | disclosed |
| US-20230151049-A1 | Compounds Useful in HIV Therapy | VIIV HEALTHCARE COMPANY (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230151049-A1 | Compounds Useful in HIV Therapy | VIIV HEALTHCARE COMPANY (US) | 2023-05-18 | — | — | US | disclosed |
| WO-2023073534-A1 | NOVEL LIPIDS FOR DELIVERY OF NUCLEIC ACID SEGMENTS | ASTRAZENECA AB (SE) | 2023-05-04 | — | — | WO | disclosed |
| EP-4126888-A1 | COMPOUNDS USEFUL IN HIV THERAPY | VIIV Healthcare Company (US) | 2023-02-08 | — | — | EP | disclosed |
| CN-115304481-A | Preparation method of dimethyl dialkyl malonate | 九江德思光电材料有限公司 | 2022-11-08 | — | — | CN | disclosed |
| WO-2021194828-A1 | COMPOUNDS USEFUL IN HIV THERAPY | VIIV HEALTHCARE COMPANY (US) | 2021-09-30 | — | — | WO | disclosed |
| EP-1178031-B1 | PROCESS FOR THE PREPARATION OF ORGANIC COMPOUNDS WITH MANGANESE CATALYSTS OR THE LIKE | DAICEL CHEM (JP) | 2012-02-01 | — | — | EP | disclosed |
| US-6548713-B2 | Efficiently producing a compound having an alkyl group or alkenyl group bonded at the alpha position of an electron attractive group, by catalytic radical addition reaction with compound of Group 5,6,7,8, or 9 | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2003-04-15 | — | — | US | disclosed |
| US-20020165416-A1 | Process for the preparation of organic compounds with manganese cataylsts or the like | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2002-11-07 | — | — | US | disclosed |
| EP-1178031-A1 | PROCESS FOR THE PREPARATION OF ORGANIC COMPOUNDS WITH MANGANESE CATALYSTS OR THE LIKE | Daicel Chemical Industries, Ltd. (JP) | 2002-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137629-A1 | Novel Lipids For Delivery Of Nucleic Acid Segments | LDLR, NPC1, NSUN2 | MEN1 3805/4885MAPT 1579/4885KMT2A 1911/4885 |
| US-20230233468-A1 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | CETP, NPC1, LCAT | MEN1 1909/4885MAPT 359/4885KMT2A 1910/4885 |
| US-20230151049-A1 | Compounds Useful in HIV Therapy | CCR5, CD4, NPC1 | MEN1 3503/4885MAPT 1067/4885KMT2A 3565/4885 |
| US-20230348362-A1 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | CETP, NPC1, LCAT | MEN1 1909/4885MAPT 359/4885KMT2A 1910/4885 |
| US-20020165416-A1 | Process for the preparation of organic compounds with manganese cataylsts or the like | SOD1, CAT, SOD3 | MEN1 4065/4885MAPT 2030/4885KMT2A 1383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.